Thu, Oct 30, 2014, 11:28 AM EDT - U.S. Markets close in 4 hrs 32 mins

Recent

% | $
Quotes you view appear here for quick access.

Protalix BioTherapeutics, Inc. (PLX) Message Board

  • all the way down. it should be one of the stocks

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ???

      my opinion this is accumulation !!!

      best regard's

      jurek

    • Not many investors are trusting the people of this company.

      Face Book - only a certain group of people profited. The group that is within the circle.

      That is how they kill the Goose that laid golden egg.

      That is why not many investors invest in TEVA---

    • I agree with everything you are saying. Im not in it for a $2 gain either, but Id feel better with some guidance. Id feel better with some news other than "profits have been taken off the table." Id feel better getting some definitive answers about milestone payments, sales, etc. Id feel better if investor relations kept scheduled phone conferences or at least bothered to send an email to me telling me that something came up. I dont think this is too much to ask. In fact, at some point it just becomes the professional thing to do. And I do think it begs the question, is PLX all that it is cracked up to be? I mean what if the next product is years away? What if Tag Alpha sales never occur? What if the next bit of news is dilution? What if IBIO technology truly is superior? Why are sales so low? Three institutional conferences and we are still below the monthly trading average? Whats up with that? Seems to me like the banks took a look at a new technology and PFE partnership and said, "we'll pass." Why is that? I dont totally believe that, but you and I dont have anything to go on besides our own hopes and wishes. Arent these guys educated? Dont they contract out a PR firm? Im talking a three paragraph release. 1 hour of work could change all this. I dont think thats too much to ask and I think as an investor this should concern you.

    • becouse FDa aproval- carrots price go higer- rabbits is angry !!!


      Normal- PLX need retest last low .

      best regard's

      jurek

    • Jarrett, the company has no interest in what the stock price is today. They are playing for the long-term. If you don't like the investment because it appears "dead' right now, then you could sell your position and try to re-buy at a lower price. That's a difficult game to play. I want to just hold so I'm in the game whenever any positive news comes out. Very frustrating but I hope that patience ultimately wins out. Plx management and employees want a high stock price even more than you do. They sold some shares so they could enjoy the fruits of their labor right now while they wait for even greater returns.

      Who cares if the stock is now 6, 7, 8 or whatever if you are not selling till it is 20. The lower price gives you a chance to buy more if you have the cash.

      I know this is an optimistic approach, but that is why I am in this stock. Not for a $2 gain today.

    • Well my two cents is tht PLX needs to do their own investor relations and PR. They hired an investor relations firm that flakes on appointments and still the only press since approval has been that executives sold millions of dollars worth of stock. In this latest interview, it appears they have received a $50 million milestone payment. One PR Newswire press release that said as much would sen this thing flying. For all we know, they got european approval, but forgot to tell anyone. I really wish someone besides me would contact them and tell them their frustration at refusing to offer guidance and information to the retail market.

      • 1 Reply to jarretthines
      • If I remember correctly, that (the receipt of a $50M milestone payment for the FDA approval) must be an error, the journalist must be wrong on that point. The correct amounts are $25M for FDA (we have that one) and $25 for EMA (not yet).

        Further down along the interview, Dr. Aviezer does make the correct statement. Quoting from the clumsy Google translation posted by Tobko: "and after obtaining permission from the FDA to market the drug Gaucher U.S. get an additional $ 25 million Pfizer, according to the agreement".

 
PLX
2.24-0.06(-2.61%)11:12 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.